टियोट्रोपियम के इंटरैक्शन

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

SPIRIVA RESPIMAT is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product [see Warnings and Precautions (5.2) ] . (टियोट्रोपियम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

SPIRIVA RESPIMAT is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, or any component of this product [see Warnings and Precautions (5.2) ] . (टियोट्रोपियम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (क्विनिडिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (ग्लूकागॉन लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

…(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (डाइफेनॉक्सिन और एट्रोपिन लेबल, चेतावनियां)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (पोटैशियम साइट्रेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (मेटोक्लोप्रामाइड लेबल, चेतावनियां और सावधानियां)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (रिबाविरिन लेबल, बॉक्स्ड चेतावनी)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (रिवास्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (रोफ्लुमिलास्ट लेबल, चेतावनियां और सावधानियां)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with albuterol. (सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (इनकोबोटुलिनमटॉक्सिनA लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use FANAPT with caution in patients who may experience these conditions. (इलोपेरिडोन लेबल, चेतावनियां और सावधानियां)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (एज़ट्रियोनम लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल लेबल, चेतावनियां)

Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (एटेनोलोल और क्लोरथैलिडोन लेबल, चेतावनियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (एरिपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (एलक्साडोलिन लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use SAPHRIS with caution in patient who may experience these conditions. (एसेनापिन लेबल, चेतावनियां और सावधानियां)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीकोडोन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (ओनाबोटुलिनमटॉक्सिनA लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (कार्बामाज़ेपिन लेबल, चेतावनियां और सावधानियां)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (कार्बिडोपा लेबल, चेतावनियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use VRAYLAR with caution in patient who may experience these conditions. (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (कोडीन लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

• Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or constipation (5.20) (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (ज़ानामिविर लेबल, चेतावनियां और सावधानियां)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

Caution should be used when ZONISADE is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity. (ज़ोनिसामाइड लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (टेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (टेपेंटाडोल लेबल, दवाओं के इंटरैक्शन)

Caution should be used when topiramate extended-release capsules are prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. (टोपिरामेट लेबल, चेतावनियां और सावधानियां)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (ट्राइफ्लुओपेराज़िन लेबल, चेतावनियां)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ट्रामाडोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ट्रामाडोल और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (ट्रैस्टुज़ुमैब लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to SPIRIVA RESPIMAT. (टियोट्रोपियम लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (डेक्सट्रोमेथॉर्फन और क्विनिडिन लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (डेक्समेडेटोमिडिन लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (ड्यूटेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (थायोथिक्सीन लेबल, चेतावनियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (नालबुफिन लेबल, दवाओं के इंटरैक्शन)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (नियोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (परफेनाज़िन लेबल, चेतावनियां)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (पाइरिडोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (पाइलोकार्पिन लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (पिमोज़ाइड लेबल, चेतावनियां)

Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (पेंटाज़ोसिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (पेथिडीन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (पैरासिटामोल और कोडीन लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (प्रोकेनामाइड लेबल, दवाओं के इंटरैक्शन)

The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli. (प्रोपोफोल लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (फेंटानिल लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (फ्लुफेनाज़िन लेबल, चेतावनियां)

Since β 1 -selectivity is not absolute and is inversely related to dose, the lowest possible dose of betaxolol should be used (5 to 10 mg once daily) and a bronchodilator should be made available. (बीटाक्सोलोल लेबल, चेतावनियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (बोटुलिनम टॉक्सिन टाइप A लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with medical therapy which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators and oxygen. (मार्गेटुक्सिमैब लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Bronchodilators, including beta 2 -agonists, should be readily available or administered concomitantly [see Dosage and Administration (2) ]. (मेटोप्रोलोल लेबल, चेतावनियां और सावधानियां)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (मेटोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (मेथाडोन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (मॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Bronchodilator: theophylline ↓ theophylline Increased dosage of theophylline may be required; therapeutic monitoring should be considered. (रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (लेवॉर्फेनॉल लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (लोक्सापिन लेबल, चेतावनियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (वाल्बेनाज़िन लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (सक्सिनिलकोलिन लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (सुगैमाडेक्स लेबल, चेतावनियां और सावधानियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (सेवोफ्लुरेन लेबल, चेतावनियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन लेबल, दवाओं के इंटरैक्शन)

Anticholinergics The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोकोडोन और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs The concomitant use of anticholinergic drugs with hydrocodone bitartrate and homatropine methylbromide may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [see Warnings and Precautions (5.9) ] . (हाइड्रोकोडोन और होमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (हाइड्रोमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (हेलोपेरिडोल लेबल, चेतावनियां)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (एसिब्यूटोलोल लेबल, चेतावनियां)

In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C max of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to… (क्लोनाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (गैलेंटामिन लेबल, दवाओं के इंटरैक्शन)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (टोब्रामाइसिन लेबल, दवाओं के इंटरैक्शन)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (टोलकैपोन लेबल, सावधानियां)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Appropriate care is advised when prescribing ERZOFRI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Flumazenil is not recommended in cases of serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, focal seizure), dysrhythmia (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), and cardiovascular collapse at presentation. (फ्लुमाज़ेनिल लेबल, चेतावनियां)

A beta 2 agonist (bronchodilator) should be made available. (बिसोप्रोलोल लेबल, चेतावनियां)

A beta 2 agonist (bronchodilator) should be made available. (बिसोप्रोलोल और हाइड्रोक्लोरोथायज़ाइड लेबल, चेतावनियां)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (बेवासिज़ुमैब लेबल, चेतावनियां और सावधानियां)

NAMZARIC may interfere with anticholinergic medications. (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (रिटुक्सिमैब लेबल, चेतावनियां और सावधानियां)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (रेगुलर इंसुलिन (ह्यूमन) लेबल, चेतावनियां और सावधानियां)

It is responsive to ephedrine or anticholinergic drugs ( 5.8 ) (रेमिफेंटानिल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

Beta blockers antagonize the bronchodilator effect of beta-receptor agonists. (लेबेटालोल लेबल, दवाओं के इंटरैक्शन)

Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (सेविमेलिन लेबल, दवाओं के इंटरैक्शन)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)